Glycemic thresholds for secretion of counterregulatory hormones and onset of physiological, symptomatic, and cognitive changes in response to hypoglycemia.

Slides:

Advertisements

Similar presentations

Diabetes Update Part 2 of 3 Division of Endocrinology

Advertisements

Management of Diabetes in the Older Person

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.

Note: this is a content review activity; items are set to animate on any click. To enable more learner interactivity/control, use action buttons and.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Copyright © 2015 by the American Osteopathic Association.

Management of Diabetes in the Older Person

Category 6 Category4 Category 5 Category 1 Category 2 Category 3

Glycemic Control, Mealtime Glucose Excursions, and Diabetic Complications in Type 2 Diabetes Mellitus P.J. Palumbo, MD Mayo Clinic Proceedings Volume.

Critiquing Cryos by Morie Gertz Blood Volume 111(11):

Glucose homeostasis: roles of insulin and glucagon. 1A.

PSYCHOLOGY IN ACTION Sixth Edition by Karen Huffman

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Copyright © 2014 John Wiley & Sons, Inc. All rights reserved.

Glycemic thresholds for subjective symptomatic awareness of hypoglycemia and for the onset of cognitive dysfunction in young and elderly nondiabetic males.

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

This CGM tracing of a 28-year-old patient with a 15-year history of type 1 diabetes demonstrates the occurrence of hypoglycemia unawareness lasting from.

Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.

Postprandial glucose flux in nondiabetic controls.

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Modern Advances in Glucose Monitoring

Page 535 Advanced Engineering Mathematics by Erwin Kreyszig

Key Insulin Side Effects*

Hypoglycaemia in diabetes

2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation: Physiologic and Educational Rationale for Changes Roger D. White, MD Mayo.

A schematic representation of the effects of early intensive glycemic control in preventing initial microvascular complications and then macrovascular.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Vertebral Fractures: Clinical Importance and Management

How Does a Gastroenterologist Demonstrate Value?

Copyright © 2014 John Wiley & Sons, Inc. All rights reserved. Chapter 20 Managing the Multinational Financial System Tenth Edition Alan C. Shapiro Multinational.

Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development.

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

Rapid-onset hypoglycemia is detected by glucose-sensing mechanisms within the VMH, which, in turn, stimulates autonomic output to enhance counterregulatory.

Prevalence of clinically significant microvascular (green) and clinically significant macrovascular (yellow) disease alone and combined microvascular and.

Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

The underlying physiological basis of the HOMA model.

Baroreflex function measured by the modified Oxford method during baseline euglycemia (circles) and hypoglycemia (triangles). Baroreflex function measured.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Effect of age, sex, race/ethnicity, and obesity on the relation of glycemic measures to Si and AIR. In linear regression models with Si as the dependent.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Representative study BG profiles from the forearm and the fingertip of six patients with diabetes. Representative study BG profiles from the forearm and.

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Glucose sensitivity of first-phase (σ1, dynamic secretion component) and second-phase (σ2, static secretion component) insulin secretion among NGT, IFG,

A total of 173 individuals were positive for GADA, and 16 of these were positive for a second antibody (11 were IA-2A positive, and 6 were ZnT8A positive).

Glycemic control and body weight over 52 weeks.

ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,

Number of antihypertensive agents prescribed for known nephropaths in phases I and II (▪), with blood pressure recordings falling outside guidelines, compared.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

Incidences of transitions between glycemic states by 25-OHD level.

Postoperative blood glucose levels and total insulin requirement.

Glycemic profile at time of recruitment of women with ICP (n = 19) and uncomplicated pregnancy (n = 23) using a CGMS (Medtronic iPro2) over 3 days. Glycemic.

The risk for incident cognitive dysfunction after an episode of severe (A) or nonsevere (B) hypoglycemia with and without accounting for the competing.

RR (with 95% CI) of total mortality (multivariate-adjusted) by duration of smoking cessation among diabetic women. RR (with 95% CI) of total mortality.

GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A:

Manhattan plot of 11,628 m/z features comparing participants who developed incident T2D versus those who did not. Manhattan plot of 11,628 m/z features.

Risk of mortality in patients with diabetes and ESRD

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Few patients with youth-onset type 2 diabetes are available to participate in clinical trials. Few patients with youth-onset type 2 diabetes are available.

Sensitivity and specificity of HbA1c, FPG, and 2hPG in identifying persons who developed diabetes within 10 years of screening among children and adolescents.

Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.

Presentation transcript:

Glycemic thresholds for secretion of counterregulatory hormones and onset of physiological, symptomatic, and cognitive changes in response to hypoglycemia in the nondiabetic human. Glycemic thresholds for secretion of counterregulatory hormones and onset of physiological, symptomatic, and cognitive changes in response to hypoglycemia in the nondiabetic human. Reproduced from Frier and Fisher (8) in Hypoglycaemia in Clinical Diabetes. Reproduced with permission of John Wiley and Sons, Chichester, U.K. Nicola N. Zammitt, and Brian M. Frier Dia Care 2005;28:2948-2961 ©2005 by American Diabetes Association